Prestige Consumer Healthcare Inc.
PBH- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001295947
No open-market purchases or sales by Prestige Consumer Healthcare Inc. insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.54B in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q2 2022
Institutional positions in Prestige Consumer Healthcare Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 285
- +6 vs. Q1 2022
- Shares held
- 51.1M
- +1.22M (+2.5%) vs. Q1 2022
- Total value
- $2.98B
- +$340.5M (+12.9%) vs. Q1 2022
- New holders
- 35
- 99 more added
- Sold out
- 29
- 121 more reduced
7 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PBH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 319 | $2.54B |
| Q1 2026 | 354 | $3.08B |
| Q4 2025 | 354 | $3.18B |
| Q3 2025 | 356 | $3.17B |
| Q2 2025 | 377 | $4.16B |
| Q1 2025 | 358 | $4.44B |
| Q4 2024 | 337 | $4.10B |
| Q3 2024 | 327 | $3.68B |
| Q2 2024 | 305 | $3.51B |
| Q1 2024 | 312 | $3.72B |
| Q4 2023 | 288 | $3.13B |
| Q3 2023 | 280 | $2.91B |
| Q2 2023 | 278 | $2.97B |
| Q1 2023 | 283 | $3.16B |
| Q4 2022 | 288 | $3.13B |
| Q3 2022 | 276 | $2.49B |
| Q2 2022 | 285 | $2.98B |
| Q1 2022 | 286 | $2.67B |
| Q4 2021 | 271 | $3.07B |
| Q3 2021 | 248 | $2.85B |
| Q2 2021 | 227 | $2.71B |
| Q1 2021 | 240 | $2.32B |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Prestige Consumer Healthcare Inc.; share changes are against Q1 2022.